Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm By: Bronstein, Gewirtz & Grossman, LLC via Business Wire October 29, 2024 at 16:00 PM EDT Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independent outside auditor CohnReznick LLP. Following this announcement, ADMA’s stock price fell $3.32 per share, or 16.33%, to close at $17.01 per share on October 10, 2024. What's Next? If you are aware of any facts relating to this investigation or purchased ADMA Biologics securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ADMA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20241029307412/en/Contacts Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm By: Bronstein, Gewirtz & Grossman, LLC via Business Wire October 29, 2024 at 16:00 PM EDT Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independent outside auditor CohnReznick LLP. Following this announcement, ADMA’s stock price fell $3.32 per share, or 16.33%, to close at $17.01 per share on October 10, 2024. What's Next? If you are aware of any facts relating to this investigation or purchased ADMA Biologics securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ADMA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20241029307412/en/Contacts Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independent outside auditor CohnReznick LLP. Following this announcement, ADMA’s stock price fell $3.32 per share, or 16.33%, to close at $17.01 per share on October 10, 2024. What's Next? If you are aware of any facts relating to this investigation or purchased ADMA Biologics securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ADMA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20241029307412/en/
